Gilead Cures 9,000 Hep C Patients—and Collects $5.7 BillionBy
The blockbuster hepatitis C drug Sovaldi has generated a staggering $5.7 billion in sales over the first half of 2014, according to an earnings report on Wednesday from Gilead Sciences. The medicine has attracted attention both for its effectiveness—it helps cure the deadly liver disease in 90 percent of patients—and its $84,000 price for a three-month course of treatment. Gilead noted on its earnings call that it believes 9,000 people have been cured so far.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.